RESULTS BY THE END OF THE NOVEMBER 2010.
The Paion AG will announce results of the Phase IIb clinical trial assessing the new short-acting intravenous anesthetic/sedative Remimazolam (CNS 7056) in patients undergoing colonoscopy.
No drug-related Serious Adverse Event has been reported.